Advertisement
ENGN vs INSM
Which Stock Would AI Choose? enGene Therapeutics Inc. (ENGN) vs. Insmed Incorporated (INSM) Stock Comparison
Key Takeaways
- ENGN is a clinical-stage biotechnology company focused on non-viral gene therapies for bladder cancer, while INSM is a commercial-stage company with approved products in respiratory diseases generating substantial revenue.
- Recent market activity shows ENGN trading near multi-year lows around $1.82 amid board transitions ahead of regulatory milestones, whereas INSM has demonstrated stronger momentum supported by product launches and positive clinical data extensions.
- Sector exposure differs markedly: ENGN centers on oncology gene therapy with high development risk, while INSM benefits from established commercial infrastructure in rare lung diseases and pipeline expansion.
- Relative performance in recent weeks reflects broader biotech volatility, with INSM showing more stability tied to revenue growth and ENGN facing greater price pressure from clinical-stage uncertainties.
- Market sentiment appears more favorable toward INSM due to its revenue-generating assets, contrasting with ENGN's reliance on upcoming regulatory catalysts.
- Both stocks operate in the biotechnology sector but present distinct risk-reward profiles suited to different investor time horizons and risk tolerances.
Introduction
This comparison examines ENGN and INSM to highlight how two biotechnology companies at different stages of development compare in the current market environment. The analysis focuses on business models, recent performance, and positioning to assist traders and investors evaluating relative opportunities in the healthcare sector. Such insights are particularly relevant for those monitoring small- and mid-cap biotech names, assessing growth drivers versus commercial execution, or constructing diversified portfolios within the life sciences industry.
ENGN Overview and Recent Performance
enGene Therapeutics Inc. operates as a clinical-stage biotechnology company developing non-viral gene therapies, with its lead candidate detalimogene voraplasmid targeting non-muscle invasive bladder cancer. The company recently completed a board transition to align leadership with upcoming regulatory and commercial milestones. In recent market activity, the stock has traded near the lower end of its 52-week range, reflecting typical volatility for development-stage biotechs awaiting clinical readouts. Sentiment has been influenced by pipeline progress and preparations for pivotal data, alongside broader sector dynamics affecting early-stage names.
INSM Overview and Recent Performance
Insmed Incorporated is a commercial-stage biotechnology company with approved therapies addressing serious lung diseases, including ARIKAYCE for nontuberculous mycobacterial lung infections and BRINSUPRI following its launch. Recent developments include positive 12-month data from an open-label extension study of treprostinil palmitil inhalation powder in pulmonary arterial hypertension, alongside preparations for second-quarter 2026 financial results. In recent weeks, the stock has shown relative resilience compared to many peers, supported by revenue contributions from its commercial portfolio and ongoing pipeline advancements.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available across thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section, based on performance metrics, strategy alignment, and adaptability. The platform offers bots with diverse trading styles, timeframes, risk parameters, and ticker coverage, enabling users to explore options suited to varying objectives. Factual ranges include bots with varying win rates, profit factors, and drawdown profiles depending on configuration. This resource provides informational value for market participants seeking data-driven tools. Explore the Trending AI Robots page for additional details.
Head-to-Head Comparison
ENGN and INSM differ fundamentally in business model: the former pursues early-stage gene therapy development with binary clinical outcomes, while the latter generates recurring revenue from approved products in respiratory medicine. Growth drivers for ENGN center on regulatory progress and clinical catalysts, whereas INSM benefits from commercial scale, product uptake, and pipeline extensions such as additional indications. Recent momentum favors INSM due to revenue visibility and data releases, contrasting with ENGN’s exposure to development-stage price swings. Risk factors include higher binary failure potential for ENGN versus execution and reimbursement considerations for INSM’s marketed assets. Sector exposure places both in biotechnology but segments them into oncology gene therapy versus rare respiratory diseases, influencing sentiment and correlation with broader market movements.
Tickeron AI Verdict
Based on observable factors including revenue generation, data consistency, and relative positioning in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to INSM over ENGN. This assessment reflects INSM’s established commercial presence and supporting clinical updates versus ENGN’s earlier-stage profile and associated volatility. The view remains probabilistic and tied to prevailing conditions rather than a definitive outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENGN is a Hold and INSM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ENGN’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s).
- ENGN’s FA Score: 1 green, 4 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ENGN’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 5 bullish TA indicator(s).
- ENGN’s TA Score: 4 bullish, 4 bearish.
- INSM’s TA Score: 5 bullish, 5 bearish.
Price Growth
ENGN (@Biotechnology) experienced а 0.00% price change this week, while INSM (@Biotechnology) price change was -1.29% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.
Reported Earning Dates
ENGN is expected to report earnings on Sep 16, 2026.
INSM is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (-4.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ENGN | INSM | ENGN / INSM | |
| Capitalization | 122M | 23.2B | 1% |
| EBITDA | -123.45M | -1.08B | 11% |
| Gain YTD | -79.845 | -38.566 | 207% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 820M | - |
| Total Cash | 258M | 1.22B | 21% |
| Total Debt | 33.4M | 580M | 6% |
INSM | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 63 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ENGN | INSM | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 66% |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 77% |
| Momentum ODDS (%) | 3 days ago 87% | 3 days ago 71% |
| MACD ODDS (%) | N/A | 3 days ago 70% |
| TrendWeek ODDS (%) | 3 days ago 89% | 3 days ago 72% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 74% |
| Advances ODDS (%) | 6 days ago 88% | 18 days ago 71% |
| Declines ODDS (%) | 14 days ago 85% | 11 days ago 73% |
| BollingerBands ODDS (%) | 3 days ago 80% | 3 days ago 73% |
| Aroon ODDS (%) | 3 days ago 88% | 3 days ago 73% |
Advertisement
ENGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ENGN has been closely correlated with TRDA. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if ENGN jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To ENGN | 1D Price Change % | ||
|---|---|---|---|---|
| ENGN | 100% | -3.70% | ||
| TRDA - ENGN | 77% Closely correlated | -3.31% | ||
| INSM - ENGN | 48% Loosely correlated | -0.46% | ||
| COGT - ENGN | 48% Loosely correlated | -1.19% | ||
| PHAR - ENGN | 40% Loosely correlated | -4.18% | ||
| ASBP - ENGN | 36% Loosely correlated | N/A | ||
More | ||||
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -0.46% | ||
| CNTN - INSM | 74% Closely correlated | -5.83% | ||
| TRDA - INSM | 51% Loosely correlated | -3.31% | ||
| ENGN - INSM | 48% Loosely correlated | -3.70% | ||
| AXON - INSM | 40% Loosely correlated | +2.12% | ||
| ARRY - INSM | 40% Loosely correlated | -5.42% | ||
More | ||||